ABUS vs VICI · P/E 5.4, rev $6.2M vs P/E 9.3, rev $3.85B
Arbutus Biopharma Corp (ABUS) versus VICI Properties Inc (VICI) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
VICI Properties Inc (VICI) is a reit - diversified company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported VICI revenue for 2024-12-31 was $3.85B. Net income was $2.72B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
Not investment advice. Open the ABUS and VICI stock pages for the full models.
Not investment advice.